SCHEMBL323215

SCHEMBL323215

CCCn1c(=O)[nH]c2ccc(C(=O)c3nc(-c4cccc(C(=O)NC(=N)CO)c4)c4ccccn34)cc2c1=O

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.39
MAPT P10636 3/20 0.36
TP53 P04637 3/20 0.36
GAA P10253 7/20 0.36
ALDH1A1 P00352 6/20 0.36
HSD17B10 Q99714 6/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 6/20 0.35
POLB P06746 1/20 0.35
CSNK1D P48730 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
KMT2A Q03164 3/20 0.34
GLA P06280 3/20 0.34
RORC P51449 1/20 0.34
MEN1 O00255 1/20 0.34
MAPK14 Q16539 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL322450 0.88 MAPT (0.39) HTR3AMAPTTP53GAAALDH1A1
SCHEMBL321532 0.88 NPC1 (0.44) HTR3AMAPTTP53GAAALDH1A1
SCHEMBL321765 0.88 RORC (0.43) GAAALDH1A1HSD17B10HPGDKDM4E
SCHEMBL14916347 0.80 PARP1 (0.36) HTR3AMAPTGAAALDH1A1HSD17B10
SCHEMBL17074448 0.80 HPGD (0.35) HTR3AGAAALDH1A1HSD17B10HPGD
SCHEMBL322513 0.79 RORC (0.44) GAAALDH1A1HSD17B10HPGDKDM4E
SCHEMBL323368 0.78 NPC1 (0.43) HTR3AMAPTTP53GAAALDH1A1
SCHEMBL322579 0.78 NPC1 (0.41) HTR3AMAPTTP53GAAALDH1A1
SCHEMBL322028 0.78 MAPK8 (0.34) MAPTGAAALDH1A1HSD17B10HPGD
SCHEMBL322448 0.75 GAA (0.39) HTR3AMAPTTP53GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 US disclosed
CN-103080111-B Imidazopyridine derivatives, its preparation method and therapeutical uses thereof 赛诺菲 2016-06-15 CN disclosed
EP-2590976-B1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-09-16 EP disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 US disclosed
EP-2590976-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
CN-103080111-A Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI SA 2013-05-01 CN disclosed
WO-2012004732-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH HTR3A 1861/4885MAPT 1577/4885TP53 1684/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH HTR3A 1861/4885MAPT 1577/4885TP53 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.